| Abstrakt: |
The study aimed to report in vitro thrombolytic and in vivo anti-nociceptive activity of methanolic extract of Caesalpinia digyna(MECD) followed by in silico PASS prediction, ADME analysis with toxicity and molecular docking study of antinociception (Cox-1, Cox-2) and thrombolytic (Tissue plasminogen activator). The clot lysis of human blood for thrombolytic study, acetic acid induced writing and formalin-induced licking in mice at several doses (50, 100, 200 and 400 mg/kg, b.w.; p.o.) of MECD for anti-inflammatory and antinoceptive activities were performed. In thrombolytic study, a significant 32.78% (P < 0.001) of the blood clot lysis revealed by MECD, while 70.32% (P < 0.001) and 3.84% were yields for positive control (streptokinase) and negative control (saline water), respectively. MECD developed a significant dose-dependent antinociception in acetic acid-induced abdominal writhing experiment while the 400 mg/kg exhibited maximum inhibition (59.27%; P < 0.001). Similarly at comparable dose concentrations, MECD produced significant (P< 0.001) dose-dependent activity in both neurogenic and inflammatory which was generated by intraplantar injections of formalin (2.5%, 20 μL/paw). In PASS prediction, isolated compounds caesalpinine A and caesalpinine C exhibited potential thrombolytic and antinociceptive activity followed by Lipinski rule for drug—like property where the compounds found to be effective in molecular docking study. The current finding suggesting MECD have potential thrombolytic and anti-nociceptive activity. |
Full text from SpringerLink